← All indications
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
Subtype terms (2)
More specific conditions that are subtypes of Psoriasis in the MeSH hierarchy.
- Arthritis, Psoriatic
93 drugs (59 approved, 34 experimental)
- Guttate Psoriasis
Drugs by status
Approved for this indication (44)
- etretinate
- spesolimab
- ulobetasol propionate
- hydrocortisone
- bimekizumab
- ustekinumab
- tazarotene
- chrysarobin
- adalimumab
- betamethasone
- clobetasol
- urea
- tapinarof
- calcitriol
- salicylic acid
- deucravacitinib
- fluocinolone acetonide
- naltrexone
- palmityl alcohol
- brodalumab
- ixekizumab
- calcipotriene
- tildrakizumab
- infliximab
- resorcinol
- methoxsalen
- cyclosporine
- etanercept
- dithranol
- fumaric acid esters
- +14 more
Phase 4 trials (33)
- vitamin d3
- esomeprazole
- tacrolimus
- efalizumab
- fluticasone
- methotrexate
- clocortolone
- dapsone
- shr-1314
- dimethyl fumarate
- capsaicin
- onabotulinumtoxinA
- ammonium lactate
- tirzepatide
- lidocaine
- coal tar
- tripterygium wilfordii
- halobetasol
- chondroitin
- mometasone
- bnt162b2
- metformin
- vedolizumab
- live attenuated varicella vaccine
- semaglutide
- rosuvastatin
- triamcinolone
- lactic acid
- live, attenuated herpes zoster vaccine
- cetyl alcohol
- +3 more
Phase 3 trials (54)
- ibi112
- icp-488
- d-2570
- hb0017
- cyanocobalamin
- trastuzumab
- serlopitant
- bcd-085
- tacalcitol
- hs-10374
- alga dunaliella bardawill
- calcipotriol
- briakinumab
- syhx1901
- pefcalcitol
- inebilizumab
- mirikizumab
- hemay005
- ak101
- roflumilast
- petrolatum, white
- nicotinamide
- lzm012
- jnj-77242113
- tar, coal
- prilocaine
- 122-0551
- turmeric
- erythromycin
- vitamin e
- +24 more
Phase 2 trials (189)
- gsk2982772
- interleukin-10
- xp23829
- bms587101
- bis-choline tetrathiomolybdate
- itacitinib
- cjm112
- agn-242428
- pioglitazone
- erlotinib
- namilumab
- pf-07038124
- mycophenolate
- abatacept
- hsk47388
- zl-1102
- qy101
- ax-158
- repaglinide
- ly2525623
- rap103
- taodan
- bexarotene
- rwj-445380
- fludarabine
- Cedirogant
- amiselimod
- delgocitinib
- ponesimod
- sulfasalazine
- +159 more
Phase 1 trials (96)
Other trials (31)
- chloranil
- anthralin
- azathioprine
- azaribine
- halometasone
- enoxaparin
- mercaptopurine
- carbonyl sulfide
- tenofovir
- zinc
- zidovudine
- bee venom
- ceramide
- imiquimod
- nitroprusside
- water
- maltodextrin
- novobiocin
- fluocinonide
- sericin
- fumarate
- paeony glucosides
- emtricitabine
- lactobacillus delbrueckii
- silymarin
- psorax35
- hpp737
- mare milk
- indirubin
- oxycholin
- +1 more
Organizations
Organization Involved with Phase 4 Indications (118)
- University of Alabama, Birmingham
- University of Michigan
- Harvard University
- Katholieke Universiteit Leuven
- The Danish Rheumatism Association
- University of Vienna
- Singapore General Hospital
- Fudan University
- Frankel, Amylynne, M.D.
- University of Rochester
- Ghent University
- Sai Life Sciences
- Humboldt University
- Piramal
- Derm Research, PLLC
- Sheth VS General Hospital
- Hamzavi Dermatology
- Dermatrials Research
- Samsung Medical Center
- University of Liverpool
- Therapeutics, Inc.
- Government of China
- Merck Serono
- GoldSkin Care
- University of Padova
- Renova Skin & Laser Clinic, Jaipur
- University of Lubeck
- Duke University
- University of Pennsylvania
- Janssen Pharmaceutica NV
- +88 more
Organization Involved with Phase 3 Indications (146)
- Harrison Clinical Research
- Deaconess Clinic
- HOPITAL LARREY - TOULOUSE
- Bakersfield Dermatology and Skin Cancer Medical Group
- Hospital Padre Bento de Guarulhos
- Colorado Medical Research Center, Inc.
- Horizons Clinical Research Center, LLC
- Horizon Research Group, Inc.
- Roivant Sciences, Inc.
- Visions Clinical Research
- G & W Laboratories Inc.
- Hudson Dermatology
- Palm Beach Research Center
- Tokai University
- Chinese Academy of Medical Sciences
- Hoosier Cancer Research Network
- Celltrion
- Mersin University
- Maruho Co., Ltd.
- Western Canada Dermatology Institute
- Walter Nahm, MD, Ph.D., Inc
- Atlanta Dermatology, Vein & Research Center
- Uludag University
- MedDerm Associates
- CABINET BATEAU BLANC - MARTIGUES
- Daiichi Sankyo
- Boehringer Ingelheim
- Gwinnett Clinical Research Center, Inc
- CMIC Co, Ltd. Japan
- Centre Hospitalier le Mans
- +116 more
Organization Involved with Phase 2 Indications (156)
- Case Western Reserve University
- Quatrx Pharmaceuticals Co
- State University of New York, Brooklyn
- Shanghai University of Traditional Chinese Medicine
- Shijiazhuang Hospital of Traditional Chinese Medicine
- Immune Technologies & Medicine GmbH
- Facet Biotech
- G. Pohl-Boskamp GmbH & Co. KG
- Psoriasis Research Institute of Guangzhou
- Royal National Hospital for Rheumatic Diseases
- Kiniksa Pharmaceuticals, Ltd.
- Hebrew University
- Durect
- Southwest Medical University
- XBiotech, Inc.
- J. W. Goethe University
- LAL Clinical Reseach e Development Ltda
- Philippine Dermatological Society
- Zalicus
- Covagen
- Actelion
- MacroGenics
- AstraZeneca
- University of Hamburg
- Deltanoid Pharmaceuticals
- Wayne State University
- Shaanxi University of Chinese Medicine
- Catawba Clinical Research
- Aristea Therapeutics, Inc.
- MetrioPharm AG
- +126 more
Organization Involved with Phase 1 Indications (54)
- NKMAX Co., Ltd.
- University of Minnesota
- Jinlin University
- Alliance Foundation Trials
- Auritec Pharmaceuticals
- Prothena Biosciences Inc
- Jinnah Postgraduate Medical Centre
- Worldwide Clinical Trials
- Richmond Pharmacology
- Sunshine Lake Pharma Co., Ltd.
- One World Cannabis Ltd.
- University of Otago
- TetraLogic Pharmaceuticals
- Medac
- Boston Pharmaceuticals
- Pharmaceutical Research Associates, Inc. (PRA)
- Covance
- Patel, Rita Vikram, M.D.
- Clinica Universidad de Navarra
- Tianjin Ever Union Biotechnology Co., Ltd.
- Atridia Pty Ltd.
- Nektar Therapeutics
- Amneal Pharmaceuticals
- Bayer
- Biotech Pharmaceutical Co., Ltd.
- Accutest Research Laboratories (I) Pvt. Ltd.
- Kang Stem Biotech Co., Ltd.
- Wright State University
- Biotie Therapies
- Novan, Inc.
- +24 more
Organization Involved with Other Experimental Indications (35)
- Government of Norway
- NeoStrata Company, Inc.
- University of Bergen
- Dalian Medical University
- University of North Carolina at Chapel Hill
- Harkány Spa Hospital, Hungary
- Xijing Hospital
- Karolinska Institute
- RWTH Aachen University
- National Center for Research Resources (NCRR)
- University of Tromso
- Eurasia Invest Ltd., Kazakhstan
- Pontificia Universidad Catolica de Chile
- Unipharm, Inc.
- Biopolis S.L.
- Chulalongkorn University
- National Research, Development and Innovation Office, Hungary
- The Michaelsen Foundation
- Université catholique de Louvain
- Arctic Nutrition AS
- Nazarbayev University Medical Center
- Universidad Católica San Antonio de Murcia
- Centre for Dermatology and Sexually Transmitted Diseases, Astana, Kazakhstan
- University of Pecs
- Korott, S.L.
- Medical University of Graz
- Glaxo Wellcome
- Philips
- Boston University
- Government of Kazakhstan
- +5 more